Conference Coverage: EHA 2024 – Focus on Multiple Myeloma
The latest therapeutic developments in multiple myeloma – how will they change our approach to treatment patterns?
Faculty Members
Shaji Kumar, MD
Mayo Clinic, Rochester, MN, USA
Sagar Lonial, MD, FACP
Winship Cancer Institute, Emory University, Atlanta, GA, USA
Bruno Paiva, PharmD, PhD
Clinica Universidad de Navarra, Pamplona, Spain
Thierry Facon, MD
Lille University Hospital, Lille, France
Mohamad Mohty, MD, PhD
Sorbonne University, Paris, France
Hermann Einsele, MD, FRCP
University Hospital Würzburg, Germany
Evangelos Terpos, MD, PhD
National and Kapodistrian University of Athens, Greece
REPORT TOPICS
- Newly Diagnosed Multiple Myeloma: Transplant Eligible
- Newly Diagnosed Multiple Myeloma: Transplant Ineligible
- Relapsed/Refractory Multiple Myeloma: Small Molecules
- Relapsed/Refractory Multiple Myeloma: Antibodies and Bispecifics I
- Relapsed/Refractory Multiple Myeloma: Antibodies and Bispecifics II
